Advances and Challenges in Biological Drug Development and Delivery to be Discussed at Symposium Hosted by the Catalent Applied Drug Delivery Institute and JLABS

SOMERSET, N.J. – June 7, 2018 — The Catalent Applied Drug Delivery Institute today announced that it is to hold a one-day symposium in partnership with Johnson & Johnson Innovation, JLABS, entitled “Advances in Drug Development and Delivery: Challenges, Patient-Centricity, and Innovative Technologies” on Tuesday, June 12, in Houston, Texas. Catalent scientists will be joined by experts from Pillsbury Winthrop Shaw Pitman LLP, MD Anderson Cancer Center, and Houston Methodist Research Institute.

This event will focus on the latest technologies for biologic therapeutics, key considerations when undertaking research and development programs, how to launch and build a biotechnology start-up, and how to incorporate patient focused design principles to promote better biologic drug performance.

The event will be hosted at JLABS at Texas Medical Center and the agenda includes the following presentations:

  • Biotech: Birth to Solid Food (how to form your company, build your team, and raise funding)

Mr. Andrew L. Strong, Partner, Pillsbury Winthrop Shaw Pitman LLP

  • Efficient Expression of Complex Proteins in Mammalian Cells

Gregory Bleck, Ph.D., Global Head R&D, Biologics, Catalent Biologics

  • Orbit: An MD Anderson Translational Engine for the Discovery and Development of Therapeutics “Antibodies”

DongXing Zha, Ph.D., Associate Director, ORBIT, MD Anderson Cancer Center

  • Importance of Formulation Development During Drug Substance Process Development

Yunsong (Frank) Li, Ph.D., Director, Process Development, Catalent Biologics

  • Beyond “Drugs”

Mauro Ferrari, Ph.D., Ernest Cockrell Jr. Presidential Distinguished Chair, President & CEO, Houston Methodist Research Institute & Director, Institute for Academic Medicine.

To find out more or to reserve a place at this event, visit: Catalent/JLABS.

Established in 2012, the Catalent Applied Drug Delivery Institute employs a multi-tiered approach to accelerate the adoption of advanced drug delivery technologies. In June 2014, the Institute created the Non-Invasive Macromolecule Delivery Consortium, with working groups looking at alternative delivery routes to injection and infusion for biologics and other large molecule therapeutics.


Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and digital health sectors. The JLABS flagship opened in 2012 in San Diego at Janssen’s West Coast Research Center, and since then has grown to eight locations including the Bay Area, Boston & Lowell, MA, Houston, Toronto and a ninth location, New York City, launching in 2018. For more information please visit

About the Catalent Applied Drug Delivery Institute

Catalent’s Applied Drug Delivery Institute was founded to serve as a link between industry and academia, advance education and training in drug delivery in academia and the industry, accelerate adoption of applied drug delivery technologies to develop better treatments, and foster industry collaboration on major issues pertaining to drug development, formulation, and delivery. It is pursuing a multi-tiered approach of research, strategic counsel, and educational programs to advance the adoption of emerging technologies.

For more details on the Catalent Institute, visit and follow the Catalent Institute on Twitter: @DrugDeliveryIns

About Catalent

Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 11,000 people, including over 1,400 scientists, at more than 30 facilities across five continents, and in fiscal 2017 generated over $2 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit

More products. Better treatments. Reliably supplied.™